Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.67 |
| ▸ | ACE | P12821 | 4/20 | 0.59 |
| ▸ | CPA1 | P15085 | 1/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761659 | 1.00 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL1987346 | 1.00 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29408691 | 1.00 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL30011266 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL31025643 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29527395 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL30011237 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL30011197 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL31025645 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| Trifluoroacetic Acid SCHEMBL31675100 | 0.94 | MME (0.60) | MMEACECPA1ACE2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366738-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | AGILENT TECHNOLOGIES INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-11992518-B2 | Molecular vaccines for infectious disease | AGILENT TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-10968269-B1 | MHC multimers in borrelia diagnostics and disease | AGILENT TECHNOLOGIES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210047383-A1 | MHC Multimers in Borrelia Diagnostics and Disease | DAKO DENMARK APS (DK) | 2021-02-18 | — | — | US | disclosed |
| US-20200347103-A1 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | AGILENT TECHNOLOGIES INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10611818-B2 | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics | AGILENT TECHNOLOGIES, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190314471-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | AGILENT TECHNOLOGIES, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10369204-B2 | Molecular vaccines for infectious disease | DAKO DENMARK A/S (DK) | 2019-08-06 | — | — | US | disclosed |
| EP-2351833-B1 | PEPTIDE-CONTAINING CULTURE MEDIUM FOR CULTURING ANIMAL CELL | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-07-18 | — | — | EP | disclosed |
| US-20120258126-A1 | Molecular Vaccines for Infectious Disease | DAKO DENMARK A/S (DK) | 2012-10-11 | — | — | US | disclosed |
| EP-2337795-A2 | MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING | Dako Denmark A/S (DK) | 2011-06-29 | — | — | EP | disclosed |
| EP-2254592-A2 | MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE | Dako Denmark A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| CN-101235081-B | Method for preparing oxytocin | WUXI KAILI PHARMACEUTICAL CO LTD | 2010-07-07 | — | — | CN | disclosed |
| EP-2197908-A2 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | Dako Denmark A/S (DK) | 2010-06-23 | — | — | EP | disclosed |
| WO-2010037402-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010037395-A2 | MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010037397-A1 | MHC MULTIMERS IN CMV IMMUNE MONITORING | DAKO DENMARK A/S (DK) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009106073-A2 | MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE | DAKO DENMARK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009039854-A2 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | DAKO DENMARK A/S (DK) | 2009-04-02 | — | — | WO | disclosed |
| CN-101235081-A | Method for preparing oxytocin | WUXI KAILI PHARMACEUTICAL CO L (CN) | 2008-08-06 | — | — | CN | disclosed |